27.1 million cr, page-18

And I don't like to say it because I'm an ASX investor, but the US is probably a better home for VLA. Management must be looking at US bio valuations and wishing VLA was there.

My heart says VLA should stay Australian (my wife is from Newcastle, and went to the University at which CAVATAK was invented), but my head says follow the money which is undoubtedly the US.

Regarding participation in the CR, I will be participating for selfish reasons - my wife had a melanoma in her 30s (removed about 5 years ago, and hopefully gone for ever) and I know the anguish of not knowing whether an innocuous looking mole-like skin discolouration is your death sentence. I'm happy to pour in some more money to try to increase the chances of survival/average life span for people afflicted. I happen to think that it could make me a good (possibly even spectactular) return, but that is not as important to me with this stock.